AC Immune (ACIU)
(Real Time Quote from BATS)
$3.11 USD
+0.05 (1.63%)
Updated Sep 4, 2024 02:32 PM ET
3-Hold of 5 3
D Value A Growth F Momentum D VGM
Income Statements
Fiscal Year end for AC Immune falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 16 | 4 | 0 | 16 | 112 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 16 | 4 | 0 | 16 | 112 |
Selling & Adminstrative & Depr. & Amort Expenses | 76 | 78 | 86 | 82 | 67 |
Income After Depreciation & Amortization | -60 | -74 | -86 | -65 | 45 |
Non-Operating Income | 0 | 0 | 7 | -1 | 5 |
Interest Expense | 0 | 0 | 1 | 0 | 4 |
Pretax Income | -60 | -74 | -80 | -66 | 46 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -60 | -74 | -80 | -66 | 46 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -60 | -74 | -80 | -66 | 46 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -57 | -72 | -84 | -63 | 46 |
Depreciation & Amortization (Cash Flow) | 2 | 2 | 3 | 2 | 1 |
Income After Depreciation & Amortization | -60 | -74 | -86 | -65 | 45 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 84.74 | 83.24 | 74.95 | 71.90 | 71.10 |
Diluted EPS Before Non-Recurring Items | -0.71 | -0.89 | -1.06 | -0.92 | 0.60 |
Diluted Net EPS (GAAP) | -0.71 | -0.89 | -1.06 | -0.92 | 0.64 |
Fiscal Year end for AC Immune falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.76 | 0.00 | 16.71 | 0.00 | 0.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.76 | 0.00 | 16.49 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 23.94 | 22.94 | 20.76 | 17.50 | 18.96 |
Income After SG&A, R&D, and Dept/Amort Expenses | -23.18 | -22.94 | -4.27 | -17.50 | -18.96 |
Non-Operating Income | -1.95 | 2.56 | -1.31 | 0.40 | 0.27 |
Interest Expense | 0.04 | 0.04 | 0.03 | 0.03 | 0.03 |
Pretax Income | -25.17 | -20.42 | -5.62 | -17.14 | -18.72 |
Income Taxes | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -25.17 | -20.42 | -5.63 | -17.13 | -18.73 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -25.17 | -20.42 | -5.62 | -17.14 | -18.73 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 98.96 | 99.23 | 94.88 | 84.13 | 84.17 |
Diluted EPS Before Non-Recurring Items | -0.25 | -0.21 | -0.06 | -0.20 | -0.22 |
Diluted Net EPS (GAAP) | -0.25 | -0.21 | -0.06 | -0.20 | -0.22 |